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Dendritic cells (DCs) play a pivotal role in determining whether the outcome 
of the immune system's encounter with antigen will be immunity or 
tolerance. Using an antibody against the DEC-205 receptor, antigens have 
been delivered specifically to DCs in vivo. Under steady state conditions, 
such presentation of antigen leads to peripheral tolerance in transgenic T 
cells, either by deletion, anergy or the induction of regulatory T cells. We 
wanted to examine whether delivery of autoantigens to DCs using this 
approach, could be used to tolerize autoreactive polyclonal T cells, thereby 
preventing autoimmunity in mouse models. We succeeded in inducing 
tolerance to the myelin oligodendrocyte protein and preventing disease in 
the experimental autoimmune encephalomyelitis model. However no halt or 
delay in onset of autoimmune diabetes was observed when insulin was 
targeted to DCs in the non-obese diabetic (NOD) mouse model. Also, 
foreign antigen-specific T cell responses could not be abolished by targeting 
antigen to DCs in the NOD mouse. These results strongly suggested that 
establishing peripheral tolerance in disease-prone polyclonal repertoires such 
 
 as in the NOD model, would be far more challenging than the previously 
studied tolerance in non-autoreactive transgenic models had been. We 
recognized that success in DC-targeting-based autoimmune therapy would 
first require a better understanding of tolerance in non-disease prone 
polyclonal T cell repertoires. Towards that end, we examined T cell 
tolerance in C57BL/6 mice. In the steady state, targeting ovalbumin (OVA) 
to DCs resulted in polyclonal CD4 and CD8 T cell tolerance. This tolerance 
was non-deletional and characterized by persistence of T cells that produced 
IFNγ, but no IL-2. CD4 dependent antibody production by B cells in vivo 
was abrogated. Also, both CD4 and CD8 proliferative responses in vitro 
were abolished. Subsequent to tolerization, depending on the strength of the 
costimulatory stimulus that the  CD4 and CD8 T cells are exposed to, 
tolerance can be reversed both in vivo and in vitro. Thus our results 
demonstrate that while tolerance in non-autoreactive polyclonal repertoires 
in steady state DC environments can be achieved, reversal of the tolerized 
state can also occur. This suggests that in autoreactive T cell repertoires in 
chronically inflamed DC environments, the prevention or treatment of 
autoimmune disease is a challenge that will require comprehensive 
understanding of the balance between immunity and tolerance.  
I dedicate this thesis to my grandmother who gave me my first lessons in 
atomic chemistry, who taught me the nature of light and who answered my 
first questions on what a cell is. She inspired me, challenged me, and always 
believed in me. And to my parents for their love and their wisdom, and for 
being there for me for every hill and mountain I climbed. 
 iii
Acknowledgements 
 
I am very grateful to my advisor Dr. Michel Nussenzweig for his guidance, 
for teaching me to think critically, and for giving me the freedom to develop 
a challenging project independently and to grow with it. The intellectually 
stimulating and diverse environment that he fosters in the lab makes it an 
exciting training ground for young scientists.  
 
I would also like to thank the chair of my advisory committee, Dr. Ralph 
Steinman for his advice and his vision.  I want to especially thank Dr. Jeff 
Ravetch for always being extremely supportive and encouraging of my 
work, and for his insightful suggestions. I am grateful to Dr. Teresa 
DiLorenzo, my external examiner, for being so enthusiastic and helpful with 
her suggestions.   
 
The members of the Dean’s Office at Rockefeller University have always 
been extremely kind and helpful. I would like to thank the Dean Dr. Sid 
Strickland for his advice and encouragement. I am especially grateful to 
Marta Delgado and Kristen Cullen, who were tremendously supportive and 
always had warm words of encouragement during the uphill times. I am also 
 iv
thankful to Cris Rosario for his help through the years and especially with 
the thesis. 
 
I am grateful to several people in the lab, who over the years have been great 
colleagues and wonderful friends. I would like to thank Daniel Hawiger who 
first introduced me to the world of dendritic cells, and with whom I 
collaborated on the early experiments. Vasco Barreto, my baymate, big-
brother, philosopher and sometimes aggravator, made life in lab very 
special. I want to especially thank Anna Gazumyan, Kevin McBride and 
Michela Di Virgilio for their advice, encouragement and never-failing 
support. I would like to thank Pierre Guermonprez, Kang Liu and Tanya 
Obukhanych for very helpful scientific discussion and insightful 
suggestions. I am grateful to Silvia Boscardin, David Bosque, Tom 
Eisenreich, Mila Jankovic, Alice Silva, Randy Lindquist, Almudena Ramiro, 
Zoran Jankovic and Virginia Menendez for being wonderful colleagues and 
for all their help over the years. I am also very grateful to Christine 
Trumpfheller, Marina Caskey and Sayuri Yamazaki from the Steinman lab 
for their generosity and support. I would like to thank Kristin Tarbell for her 
help and sharing her experience with me. A special word of thanks to my 
 v
collaborator Dr. Gabrielle Grunig for her advice, encouragement and 
kindness over the years. 
 
I am so grateful to my family- my mother and father and brother Nitin, my 
grandmother and grandfather, my aunt Krishna and uncle Ken- for the love 
and unconditional support they have always given me. They have been my 
beacon of hope and courage through everything. I could not have 
accomplished this without my friends, who have been my second family- 
Antony and Krishna whose constant encouragement and scientific insight I 
could not have done without; Sriram whose moral support and help with 
four- handed experiments I am so grateful for; Rajani who first taught me 
how to pipette as a naïve undergrad many years ago and was there for me 
again when I most needed advice and encouragement; Feroz, Lenz, Ranga 
and Oli, whose love, humour and encouragement from across the oceans 
carried me through the hard times. And for those who are not with me, your 
love, your dreams and your spirit will always be with me.  
 vi
Table of Contents 
Acknowledgements ...................................................................................... iv 
Table of Figures ......................................................................................... viii 
Chapter 1. Introduction ................................................................................1 
Central Tolerance ........................................................................................1 
Peripheral Tolerance ...................................................................................4 
Dendritic Cells in Immunity and Tolerance.................................................6 
Mechanisms of Peripheral Tolerance ........................................................10 
Dendritic Cells and Polyclonal T cell Tolerance: .....................................15 
Questions and an Outline of Experimental Systems ..................................15 
Chapter 2. Materials and Methods ............................................................18 
Chapter 3. Targeting of antigen to DCs in an autoimmune disease 
model ........................................................................................24 
Chapter 4. Targeting of Antigen to DCs in NOD mice ............................36 
Chapter 5. Tolerance in non-disease polyclonal repertoires ...................50 
Chapter 6. Discussion..................................................................................74 
Concluding Remarks ..................................................................................87 
References.....................................................................................................89 
 
 vii
Table of Figures 
 
 
Figure 1. Vaccination with αDEC/MOG prevents EAE in C57BL/6 wild 
type mice..................................................................................... 31 
Figure 2. Characterization of the hybrid αDEC/INS and III/I0/INS 
antibodies.................................................................................... 33 
Figure 3. Chronic treatment with αDEC/INS did not prevent or delay onset 
of diabetes................................................................................... 35 
Figure 4. αDEC/GAG p41 generates IFNγ responses in B6.H2g7 mice. ..... 43 
Figure 5. αDEC/GAG p41 generates IFNγ responses in CD4 T cells in NOD 
mice............................................................................................. 45 
Figure 6. Adeno/GAG p41 generates IFNγ responses in CD8 T cells in NOD
.................................................................................................... 47 
Figure 7. αDEC/GAG p41 does not tolerize αGAG p41-specific CD4 IFNγ 
responses in NOD mice. ............................................................. 49 
Figure 8. Design and characterization of the αDEC/OVA hybrid antibody. 
.................................................................................................... 61 
Figure 9. αDEC/OVA generates detectable IFNγ and IL-2 responses in CD4 
and CD8 cells in C57BL/6 mice................................................. 63 
Figure 10. CD4 T cells from C57BL/6 mice treated with αDEC/OVA prior 
to immunization, show reduced levels of IL-2 but not IFNγ, 
following tolerization regimen. .................................................. 65 
Figure 11. CD4 T cells from C57BL/6 mice treated with αDEC/OVA prior 
to immunization, show increased levels of IL-10, following 
tolerization regimen.................................................................... 67 
Figure 12. Single or multiple doses of αDEC/OVA prior to immunization, 
abrogates antibody production in C57BL/6 mice. ..................... 69 
 viii
 ix
Figure 13. CD4 T cells from mice treated with αDEC/OVA prior to 
immunization, do not proliferate in vitro in response to antigen.
................................................................................................... 71 
Figure 14. CD8 T cells from mice treated with αDEC/OVA prior to 
immunization, do not proliferate in vitro in response to antigen
................................................................................................... 73 
Chapter 1 
Introduction 
 
Central Tolerance 
The immune system has evolved to recognize foreign antigen from self 
antigen so that it can respond to invaders and protect the host, while 
remaining tolerant to self. The continual ability to make this distinction is 
fundamentally important in avoiding self-destructive immune responses and 
was recognized as such by Ehrlich and Morgenroth at the turn of the last 
century (1). They referred to this as horror autotoxicus. Owen and Hasek (2, 
3) demonstrated that encounter with foreign tissue during embryonic 
development leads to life-long tolerance against the antigens expressed in 
the tissue. These results were extended by Billingham and Medawar, when 
they demonstrated acquired tolerance to foreign blood cells and skin grafts 
in animals that had been exposed during neonatal development to tissues 
from the donor(4). These results were interpreted to mean that the 
developing immune system was malleable and if a foreign subtsance was 
introduced early enough, it would induce tolerance rather than immunity. 
Burnet, in 1957, synthesized these experimental findings into the theory of 
clonal selection, which postulated that lymphocytes with receptor 
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specificities against antigens present during embryonic development, would 
be selectively eliminated by a process of deletion. To this day Burnet’s 
theory forms the fundamental framework for understanding how 
immunological tolerance is induced.  
 
The clonal selection theory has been directly validated by studies that 
observed the deletion of T cells in the thymus, bearing T cell receptors that 
recognize endogenous antigens in the context of the Major 
Histocompatibility (MHC) Class I and II molecules (5-7). Immature 
autoreactive thymocytes enounter their cognate antigen during development 
and get deleted by apoptotic cell death (8) that ensures the absence of these 
clones from the mature repertoire that enters the periphery from the thymus. 
This process, referred to as negative selection, was thought to be mediated 
by bone marrow- derived antigen presenting cells (APCs) (9, 10), likely 
thymic dendritic cells (DCs). Subsequently thymic medullary DCs were 
shown to mediate thymic deletion both in vitro (11) and in vivo (12).  
 
Central tolerance to self-antigens has to account for two categories of 
antigens: those that are ubiquitously expressed and those that have tissue 
specific distribution (13). It has been reported that many tissue specific 
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antigens are expressed promiscuously (14, 15) in medullary thymic 
epithelial cells (mTECs) under the regulation of AIRE (autoimmune 
regulator), a gene identified from patients with a rare autosomal recessive 
disorder known as autoimmune polyglandular syndrome type 1 (APS-1). 
Affected patients develop spontaneous autoimmune disease targeted 
pimarily at endocrine organs (16). In mice deficient in AIRE expression in 
mTECs, the expression of  a subset of tissue specific antigens is abrogated, 
resulting in the failure of negative selection in the thymus (17-20).Studies 
suggest that in addition to AIRE there are other, as yet unknown factors that 
direct expression of tissue specific antigens in mTECs and are thus involved 
in central tolerance (18). It has been shown that mTECs can directly mediate 
negative selection of CD8 T cells against tissue specific antigens by 
presentation on their MHC Class I molecules. Thymic DCs on the other 
hand can acquire tissue specific antigens from mTECs either by uptake of 
apoptotic cells, or nibbling of surface membranes of live cells, then process 
for MHC class I and class II presentation, and delete both CD8 and CD4 T 
cells (21). 
 
Negative selection in the thymus, while presenting a sophisticated and 
coherent model for self tolerance, cannot explain every instance of tolerance 
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encountered through the life of the animal. For instance, some self antigens 
are only expressed in the body after the stage of early T cell development in 
the thymus (22), and most innocuous environmental antigens that are 
tolerated are also unavailable for antigen presentation during negative 
selection. Additionally, it has been shown that some low-affinity 
autoreactive T cells escape thymic negative selection because the strength of 
signal transduction upon TCR engagment by the cognate antigen-MHC 
complex is below the threshold required for induction of apoptosis (23).The 
fact that despite these limitations of thymic negative selection, and the 
documented presence of autoreactive T cells in the periphery (24, 25) most 
individuals do not succumb to autoimmunity, suggested the existence of 
extrathymic mechanisms to enforce tolerance.  
 
Peripheral Tolerance 
It was observed that mature T cells could be tolerized to non-self antigens 
that were either injected (26, 27) or expressed as endogenous antigens (28) 
independent of thymic selection. This form of extrathymic tolerance was 
called peripheral tolerance and both CD4 and CD8 T cells were shown to be 
potential targets of this form of tolerance (27, 29, 30). Peripheral tolerance 
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of T cells was shown to abrogate both T-helper dependent antibody 
production (31) as well as autoimmune disease (29, 32).  
 
The initial challenge to the study of peripheral tolerance was how to exclude 
the involvement of thymic mechanisms in the analysis of tolerance 
induction. An early solution to the problem, was the use of antibodies that 
blocked the presentation of antigens on endogenous MHC molecules during 
thymic development (33). Another approach involved the transfer of H-Y 
specific TCR transgenic T cells into male recipients that express the H-Y 
antigen. Transferred T cells intially proliferated in response to the H-Y 
antigen in the periphery, but were later subjected to extrathymic deletion and 
anergy (28). Similar results were obtained in models that studied T cell 
response to novel, extrathymic antigens, transgenically expressed under 
tissue specific promoters (34-36). While T cell production and survival in 
the thymus was unchanged in these experiments, autoreactive clones in the 
periphery were deleted, thus making a strong case for a mode of tolerance 
that was solely regulated in the periphery. 
 
That there is an intricate regulation of peripheral tolerance, was underscored 
by studies where the transgenic expression of novel proteins in the periphery 
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did not result in tolerance (37, 38) and sometimes even led to autoimmunity 
(39). It was observed that newly made peripheral proteins were ignored by 
antigen- specific T cells, but could cause autoimmunity if their expression 
was concurrent with viral infection or ectopic expression of IL-2 (40-42). A 
significant observation was that the expression levels of novel proteins could 
influence the fate of antigen specific T cells. If a protein was expressed at 
high levels,  it favored the deletion of T cells (43-46). All these findings 
point to an extremely delicate balance between the regulation of tolerance 
and immunity that depends on multiple checkpoints. Antigen presenting 
cells as the initiators of the cascade that leads to an immune response are 
therefore at the apex of this regulation. 
 
Dendritic Cells in Immunity and Tolerance 
As antigen presenting cells, dendritic cells (DCs) have been revealed in the 
last two decades to be critical to the balance between tolerance and 
immunity. Soon after their discovery (47-49), dendritic cells, so called 
because of their long astral processes, were shown to be potent stimulators 
of T cells. They were able to initiate primary immune responses (50-53), 
induce polarization in T cells, to generate Th1 and Th2 responses (54), and 
most recently Th17 responses (55) and were used successfully for 
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therapeutic immune reponses in human patients (56). DCs efficiently 
process peptides from soluble antigens (57) and also present them on both 
class I and class II complexes in vitro (57, 58) and ex vivo (59). DCs also 
uptake dying cells and process and present their antigens to T cells (60, 61). 
Recently in work described below DCs have been targeted in vivo with Class 
I and Class II antigens, for processing and presentation to CD4 and CD8 T 
cells (62-64). 
 
DCs are found throughout the body so they come into contact with antigens 
in tissues all over. They are present in skin (65), the airways (66), blood 
(67), lymphatics (68), lymphoid organs (48) and interstitial parenchymal 
spaces (69). Dendritic cells are an ephemeral population with a life-span of a 
few days (49, 70), however they are highly mobile and migrate upon antigen 
enounter to lymphoid organs (71). Also it was recently shown that DCs 
divide in situ in peripheral tissues, and peptide-MHC complexes are 
transferred to the daughter DCs (72). 
 
DCs use several types of receptors for antigen uptake such as Fc receptors of 
Type I, II (73) and III (74), complement receptors (75), scavenger receptors 
(76) and C-type lectin receptors (77, 78). In recent years, the C-type lectin 
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receptors have been targeted by genetically engineered antibodies carrying 
antigens for specific delivery to DCs. The first lectin receptor to be  targeted 
was the DEC-205 receptor, which has an unusual trafficking pathway that 
passes through late endosomes leading to effective antigen presentation (79). 
Subsequently the DC-SIGN receptor (80), DCIR2 (63), and Langerin (81), 
of the lectin family of receptors, have been targeted for antigen delivery to 
the DCs. 
 
The initiation of immunity by DCs is regulated by the presence of 
costimulatory, activating molecules and receptors on their surface as well as 
the induction of cytokines. Some of the important costimulatory molecules 
are Ig family members such as CD80 and CD86 (82), B7-DC (83), PD-L1 
(84), PD-L2 (85) and TNF family member CD30 (86). These molecules 
form ligand-receptor pairs with their counterparts on T cells such as CD28 
(87), CTLA-4 (88) and PD-1 (84).  DCs express several classes of receptors 
such as Toll-like receptors (TLRs), Tumor Necrosis Factor family receptors 
(TNF-Rs) and cytokine receptors. The TLRs are involved in the recognition 
of signals associated with infection and tissue damage, and are therefore 
seen as a link between innate and adaptive immunity. The binding of their 
pathogenic ligands such as lipopolysaccharide (89, 90) peptidoglycans, CpG 
 8
(91) and others, lead to a cascade of downstream signaling resulting in the 
activation of transcription factors such as NF- κB involved in survival, 
differentiation and inflammation responses (92). In addition to their role in 
antigen uptake, Fc receptors can also trigger both activatory and inhibitory 
signaling cascades (93-95). CD40 is an important TNF family receptor that 
is involved in  feedback activation of DCs by CD4 helper cells that 
upregulate CD40L after intial activation (96, 97). Upon activation DCs 
upregulate the production of pro-immune cytokines such as IL-12 (75) and 
IFNα (98). The concerted involvement of  all these DC activation pathways, 
leads to the activation of T cells and consequent immunity. 
 
The role for DCs in tolerance was demonstrated by the targeting of antigens 
to the DEC-205 receptor in the absence of adjuvant (64). An antibody 
against the DEC-receptor expressed mainly on CD8 DCs, was cloned  and 
fused to a peptide from hen egg lysozyme (HEL) (αDEC/HEL). When DCs 
were targeted in vivo with this construct in the absence of adjuvant, they 
presented antigen to HEL-specific T cells and the consequence of this steady 
state presentation was the deletion of the T cells and ultimately tolerance 
against future challenge with HEL. In contrast if the αDEC/HEL was 
delivered along with an inflammatory stimulus, the consequence of antigen 
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presentation to T cells was persistent activation and immunity. The model 
that emerged from this paradigmatic study was that the context in which 
DCs in vivo present antigen to T cells, governs the fate of the T cells. Under 
normal steady state conditions, defined as the absence of inflammation or 
infection, the presentation of antigen by DCs leads to T cell tolerance. In 
contrast, under conditions of inflammation and tissue injury, the DCs 
acquire an activated phentotype and the presentation of antigen to T cells in 
this context leads to immunity against the antigen (99). 
 
Recently the DCIR2 molecule on the CD8- subset of DCs was targeted for 
antigen delivery by a monoclonal antibody and the consequence of such 
targeting was tolerance. Using transgenic T cells against OVA, the 
presentation efficiencies of the DEC-205 and DCIR2 receptors was 
compared. It was demonstrated that the DCIR2 targeting strategy leads to 
superior Class II presentation, while the DEC-205 targeting strategy leads to 
better Class I presentation of antigen to T cells (63). 
 
Mechanisms of Peripheral Tolerance 
DCs can induce tolerance in T cells by several different mechanisms. T cell 
ignorance defined as the lack of antigen recognition was observed in several 
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cases of endogenously expressed novel antigens (40, 41) and was postulated 
to be responsible for some forms of tolerance. However as a mechanism it is 
a very limited explanation for the life-long tolerance against a wide-range of 
self and harmless non-self antigens that an animal constantly encounters. 
 
Deletion is a characteristic mechanism of peripheral tolerance observed 
among responding T cells (28, 33, 35, 45, 46). A characteristic feature of 
such deletion is an initial clonal expansion, preceeding the disappearance of 
autoreactive T cells. Peripheral deletion has some resemblance to activation 
induced cell death, an important pathway to terminate immune responses. 
There have been examples of Fas induced death of T cells in tolerance (100) 
and TNF involvement (101), but other mechanisms of deletion may exist 
that are yet to be discovered. 
 
Anergy as a form of tolerance involves a state of unresponsiveness of T 
cells, that otherwise remain viable and persist for long periods of time in an 
organism (102). Initially anergy that resulted from incomplete signaling to 
the T cells was reported. In such cases anergy was  maintained by a block in 
the Ras/MAP kinase pathway, could be reversed by IL-2 or anti-OX40 
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signaling, and usually did not result in the inhibition of effector functions 
(82, 103, 104). 
 
 Other forms of anergy have now been shown that require complete initial 
activation of the T cells by stimulatory CD28 and inhibitory CTLA-4 
signaling (105). We have shown that upon antigen targeting to steady state 
DCs, transgenic T cells against the myelin oligodendrocyte protein were 
rendered anergic. This anergy required initial activation of T cells and was 
characterized by the upregulation of CD5. Upon blocking with αCD5 
antibody, we could restore antigen-specific responsiveness of the T cells in 
vivo. Thus CD5 in this model, acts as an inhibitor of T cell signaling (106). 
CD5  is a glycoprotein that acts as both a positive and negative regulator of 
T cell activation (107-111). The intracellular domain of CD5 contains 
sequences  resembling both an immunoreceptor tyrosine-based activatory 
motif (ITAM) and an inhibitory motif (ITIM), that may explain the dual 
nature of CD5 function(112).  
 
One of the pathways of anergic tolerance involves an early block in tyrosine 
kinase activation, which predominantly inhibits calcium mobilization, and 
an independent mechanism that blocks signaling through the IL-2 receptor 
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(102). The reduction in IL-2 levels has been shown to be an important 
element in antigen-specific anergy, and results in an anti-proliferative state 
of the T cells (113-115). Thus anergy has several pathways, and is an 
important mechanism for tolerance in the periphery. 
 
Regulatory T cells (T regs) have become an intensely studied subset of T 
cells in recent years. It was observed that early thymectomy of mice causes 
general autoimmune disease (116). This observation was explained by an 
apparent decrease of CD4+CD25+ cells in thymectomized animals, which 
was later confirmed by successful prevention of autoimmunity by transfer of 
syngenic CD4+CD25+ cells (116). In vitro, CD4+CD25+ cells were shown 
to suppress proliferation of other cells by IL-2 production in a cell contact- 
dependent manner that also required TCR activation of the CD4+CD25+ 
cells.  Recently it has been shown that antigen-loaded mature DCs can 
induce expansion of CD4+CD25+ T cells in vitro, and that these cells can 
actively suppress CD4+CD25- proliferation in response to splenic APCs 
(117). This approach was then used to expand CD4+CD25+ transgenic T 
cells from a non-obese diabetic strain to prevent and treat autoimmune 
diabetes (118, 119). CD4+CD25+ suppressors specifically express the 
transcription factor Foxp3, which regulates their development and 
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function(120). Mutations in Foxp3 lead to widespread autoimmunity (120-
122). It was shown that antigen targeting to the DCs in minute doses in 
steady state in vivo, led to the conversion of CD4+CD25- effector cells into 
CD4+ CD25+ Foxp3+ T cells (123). These cells require IL-2 for their 
maintenance and activation and the lack of IL-2 results in reduced numbers 
of these cells in vivo (124-126). In contrast to the requirement of cell contact 
for in vitro suppression, there are many reports that indicate that cytokines 
such as IL-10 and TGF-β are needed in vivo for mediating suppression or 
conditioning a suppressive milieu (127, 128). Another subset of T regs is 
made under tolerogenic conditions and produces IL-10 which has been 
shown to have suppressive function in vivo in conditions of inflammation 
(129). T regs are therefore an important component of the regulation of T 
cell tolerance in vivo. 
 
Thus the establishment and maintenance of tolerance in the periphery is 
intricately regulated by the interdependence of DCs and T cells and their 
relationships with other cells of the immune system. 
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Dendritic Cells and Polyclonal T cell Tolerance: 
Questions and an Outline of Experimental Systems 
To study peripheral tolerance DCs were targeted by antigen using an αDEC-
205 antibody, and transgenic T cell models were used to study the outcome 
of such presentation of antigen. It was observed that under steady state, 
presentation of antigens to the T cells led to T cell tolerance and depending 
on the model studied, tolerance was achieved by deletion (62, 64), anergy 
(106), or the induction of regulatory T cells (123). Based on these studies, 
we decided to examine whether such targeting of antigen could lead to T cell 
tolerance in an autoimmune disease model and whether such tolerance 
would result in prevention and treatment of the disease. 
 
Autoimmunity is the breakdown of tolerance against self, and subsequent 
tissue destruction by autoreactive T cells and B cells. While genetic pre-
disposition to autoimmunity leads to the selection of autoreactive T cells 
during thymic selection, peripheral tolerance check points also break down 
in individuals that are autoimmune. Thus the induction of peripheral 
tolerance by a strategy such as the one described above would help to keep 
in check autoreactive T cells in the periphery.  
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The animal models we chose for these studies, were the experimental 
autoimmune Encephalomyelitis model (EAE) (130, 131), an induced, acute 
mouse model for mutiple sclerosis, and the Non-Obese-Diabetic Mouse 
(NOD) (132), which is a spontaneous, chronic model for autoimmune Type 
1 diabetes. The myelin oligodendrocyte peptide (MOG) (35-55) was the 
autoantigen against which tolerance was examined in the EAE model. In the 
NOD model, the 9-23 peptide from the β chain of insulin was used for 
targeting therapy.  
 
Our results showed that targeting of MOG antigen to the DCs in the EAE 
model leads to tolerance and prevention of progression to disease. In the 
NOD model, however chronic targeting of insulin could not prevent 
development of disease. The difference in therapy outcomes in the two 
models, highlighted the need for a better understanding of tolerance in 
polyclonal repertoires since all the previous studies on the outcome of 
antigen targeting to DCs had been done in transgenic T cell models. As the 
first step in understanding polyclonal tolerance, we examined the C57BL/6 
model, a non-disease prone repertoire, for tolerance to CD4 and CD8 
antigens from Ovalbumin.  
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The results described in this thesis, show that antigen targeting to DCs in 
non-disease prone mice leads to polyclonal CD4 and CD8 tolerance. This 
tolerance is non-deletional, as the cells persist with alterations in their 
effector cytokine profiles. The tolerized CD4 T cells, lose the ability to make 
IL-2, but not IFNγ. Tolerized CD4 T cells are unable to provide help to B 
cells for antibody production and thus humoral tolerance is established. CD4 
and CD8 cells that have been tolerized in vivo lose their ability to proliferate 
in response to antigen. Stimulation with αCD28 in vitro and αCD40 in vivo 
leads to a reversal of tolerance.  
 
The reversible nature of the tolerance induced in a non-disease polyclonal 
repertoire suggests that establishment and maintenance of tolerance in 
disease models will be a challenge, since the immune environment in such 
cases is chronically inflamed. Antigen presentation in that context by DCs, 
to low affinity disease-prone polyclonal T cells could potentially lead to 
immunity or reversal of tolerance. These results provide important insight 
for the future development of  successful DC-based therapeutic strategies for 
autoimmune disease. 
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Chapter 2 
 
Materials and Methods 
 
Mice: All mice used in experiments were maintained under specific 
pathogen free conditions. 5-8 week old B6.SJL (CD45.1), NOD/LtJ, and 
C57BL/6 mice were purchased from Jackson Laboratory. B6.H2g7 were 
maintained by breeding. The mice were used according to institutional 
guidelines. Protocols were approved by the Institutional Animal Care and 
Use Committee at The Rockefeller University. 
 
Mice were injected subcutaneously with protein in complete freund’s 
adjuvant (CFA) and intraperitoneally (i.p) with chimeric antibodies.  
 
Immunizations: Mice were primed either once i.p. or multiple times with 
5µg αDEC/peptide antibodies, or with 5μg αDEC/peptide antibody in 
conjunction with 50μg αCD40 (clone IC10) (as indicated in Results) or the 
same doses of αCD40 alone or with 100µg of LPS-free OVA (Seikagaku 
Corp.) precipitated in alum (Pierce Chemical Co.)). Antibodies were elicited 
by boosting the mice once i.p. with 1µg OVA-NP11, which is a conjugate of 
 18
11 molecules of the hapten (4-hydroxy-3-nitrophenyl) acetyl (NP) with the 
carrier protein (OVA). 
 
EAE induction: C57BL/6 females 6-8 weeks old, were injected with 100μg 
MOG peptide in CFA (Difco) (200μl total) divided into two parts and 
injected into each flank. This was immediately followed by i.p injection with 
200ng Pertussis Toxin (List BioLabs) in PBS. Another dose of Pertussis 
Toxin (PTX) was injected 48 hours later. CFA used for injection was 
enriched with mycobacterium TB (10ml CFA +40 mg M. TB from Difco). 
 
Diabetes Experiments: For all diabetes experiments, development of 
diabetes was monitored with chemstrips (Roche Applied Science), which 
detect urine glucose above 150 mg dL–1. A mouse was considered diabetic 
on the first of three consecutive readings of high urine glucose. Diabetes was 
monitored from the time mice were 11 weeks old, until they were 25-30 
weeks old. 
 
Adeno/GAG p41 immunization: Mice received one dose (1x107 PFU per 
mouse) of recombinant adenovirus/GAG p41 intramuscularly (i.m). 
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Construction and production of the hybrid antibodies:The entire cDNA 
encoding chicken OVA was cloned in frame with the carboxyl terminus of 
the heavy chain of mouse αDEC-205 or isotype control III/I0 antibodies. 
Likewise, a 52 base pair sequence comprising amino acids 9-23 from the 
insulin β chain peptide, was cloned into the antibodies to produce 
αDEC/INS or III/I0/INS. Hybrid antibodies were produced by transient 
transfection in 293T cells using calcium phosphate as described previously 
(64), and the fusion antibodies were purified on Protein G columns (GE 
Healthcare). They were assayed for binding to DEC-205 expressed stably on 
the surface of CHO cells, provided by C.G. Park (The Rockefeller 
University, New York, NY). Titrations ranging from 5μg/ml to 0.01μg/ml 
were tested, and the binding was detected using a secondary αmouse IgG. 
 
Peptide libraries:Peptides for OVA and GAG p41 were synthesized in 
collaboration with the Proteomics Resource Center, The Rockefeller 
University. For in vitro restimulation assays, the OVA peptide 75 (epitope 
265-279 EKLTEWTSSNVMEER) was used, which consists of both Class I 
and Class II epitopes. For GAG p41 experiments, the entire peptide library 
of GAG p41 was pooled. 
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Intracellular cytokine staining: Intracellular IFNγ and IL-2 production by 
CD4 and CD8 T cells after immunization, was evaluated using bulk 
splenocytes incubated with 2 µM of the OVA or GAG p41 peptide or 
medium alone in the presence of 2 µg/ml of costimulatory •CD28 antibody 
(clone 37.51). Cells were cultured for 6 h in the presence of brefeldin A (BD 
Biosciences), incubated with CD16/CD32 antibody to block Fc receptors, 
and stained with anti-mouse CD4 (clone GK 1.5), CD8 (clone 53-6.7), and 
CD3 (clone 145-2C11) antibodies for 15 min at 4°C. After fixation with 
Cytofix/Cytoperm Plus (BD Biosciences), cells were stained for intracellular 
IFNγ- (XMG1.2) for 15 min at room temperature. All mAbs were purchased 
from BD Biosciences. Data was collected using FACSCalibur and analyzed 
using FlowJo software (Tree Star). 
 
In vitro Proliferation Assay: We used CFSE (107 cells/ml, 1 µM, 10 min, 
37°C; Invitrogen) dilution to assess proliferation of primed T cells in 
response to antigen. Bulk splenocytes were labeled with CFSE, and added at 
500, 000 cells per well, in the presence of OVA peptide (2 µg/ml), medium 
alone, or •CD3 (0.1 µg/ml) and •CD28 (2 µg/ml; positive control) for 4 days 
in 1 ml round-bottom tubes. 
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ELISA:For the detection of NP- or OVA-specific antibodies, high-binding 
ELISA plates (Costar) were coated overnight with 5 µg/ml NP2-BSA 
(Biosearch Technologies) or OVA protein (Sigma) in PBS. Plates were then 
washed three times with PBS-Tween 20 0.02% and blocked with PBS-BSA 
1% for 1 h at room temperature. Serial dilutions of the sera in PBS-BSA 
0.25% were incubated for 2 h at room temperature and visualized with goat 
•mouse IgG Fc-specific antibody conjugated to horseradish peroxidase 
(1:2,000; Jackson ImmunoResearch Laboratories) followed by colorimetric 
assay using 1-Step ABTS. OD405 was measured using a VERSAmax 
microplate reader (Molecular Devices). Titers represent the highest dilution 
of serum showing an OD405 >0.1. The results are presented as the log10 
antibody titer of each individual mouse.  
 
LUMINEX Assay for cytokines: 14 days after immunization, bulk 
splenocytes were isolated and cultured with or without αCD28 in the 
presence of peptide or medium alone for 72 hrs. The supernatants were then 
harvested and assayed on the LUMINEX instrument using the Biosource 
Multiplex Bead Immunoassay kit for detection of TNFα, IFNγ, IL-17,       
IL-10, and IL-4. 
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Statistical Analysis: All comparisons between groups used Welch’s t-test to 
reject the null hypothesis that the means of the groups being compared are 
identical. The Welch’s t-test is a modification of the standard Student’s t-test 
which can be used to compare groups with different variances (133). The 
null hypothesis was rejected if the p-value was less than 0.05. Analysis was 
performed using MATLAB (Mathworks, MA). Error bars represent one 
standard error of the mean. 
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Chapter 3 
Results Part I 
 
 
Targeting of antigen to DCs in an autoimmune disease model 
 
The ability to establish peripheral T cell tolerance in transgenic models 
against antigens targeted to DCs, suggested that a similar targeting approach 
could be used to deliver self-antigens to DCs for presentation to autoreactive 
polyclonal T cells in mouse models of autoimmune disease. If such an 
approach resulted in tolerance of autoreactive polyclonal T cells, it would be 
a promising advance towards therapy of autoimmune disease.  
 
We chose the mouse model of experimental autoimmune encephalomyelitis 
(EAE), to examine the consequences of targeted self-antigen delivery to 
DCs. EAE resembles the human neurodegenerative disorder- multiple 
sclerosis (MS), and is mediated by the destruction of the neuronal myelin 
sheath by T cells that are specific for myelin epitopes. In mice, EAE can be 
induced by immunization with myelin oligodendrocyte (MOG) peptide  
35-55. This immunization leads to the activation of MOG-specific CD4 T 
cells, which then home into the central nervous system by infiltrating the 
blood-brain barrier, ultimately leading to neuronal destruction (131). We 
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decided to examine the consequences of targeted delivery of MOG peptide 
to DCs, on the pathology of the disease. 
 
Daniel Hawiger, designed hybrid DC targeting antibodies that consisted of 
the MOG 35-55 peptide fused to the carboxyl terminus of the cloned αDEC 
(referred to as αDEC/MOG) and isotype control (III/10 /MOG) heavy chains 
(Figure 1A). Using these antibodies we demonstrated that MOG- specific 
transgenic CD4 T cells, could be tolerized by targeting MOG peptide to 
steady state DCs for presentation to T cells (106). We therefore wanted to 
determine whether αDEC/MOG targeting to DCs would lead to the 
prevention of MOG peptide-mediated disease in the EAE model. Disease 
was induced by activating MOG peptide-specific T cells by injection of 
MOG peptide in CFA, followed by injection of Pertussis Toxin (PTX) to 
breech the blood-brain barrier.  C57BL/6 mice were injected with 
αDEC/MOG or isotype control III/10/MOG or PBS and 7 days later 
immunized with 100μg MOG peptide in CFA subcutaneously, followed by 
two doses of PTX. The condition of the mice was monitored daily. Within 
two weeks after immunization with MOG peptide in CFA followed by PTX, 
controls injected with PBS or III/10/MOG had developed symptoms of EAE. 
In contrast, all but one of the αDEC/MOG- treated mice remained 
 25
completely disease-free, and the one mouse that developed symptoms 
showed only very mild disease (Figure 1B). The mice were monitored for 
the next 10 days and no significant change in their condition was detected.  
 
To examine whether the prevention of disease in αDEC/MOG treated mice, 
was due to some form of T cell tolerance, we assessed homing capacity of 
CD4 T cells to the spinal cords in tolerized versus control mice. While 
increased numbers of CD4 T cells were detected in spinal cords from control 
treated mice that showed symptoms of EAE, no such cells were found in 
spinal cords from mice that were treated with αDEC/MOG prior to 
immunization with MOG peptide in CFA and PTX (Figure 1C). Thus 
treatment with αDEC/MOG blocked the homing capacity of CD4 T cells to 
the spinal cord and effectively prevented induction of EAE. 
 
The success of the dendritic cell targeting strategy to prevent disease in EAE 
which is an induced acute autoimmune model, encouraged us to attempt the 
challenge of therapy in a spontaneous chronic mouse model of 
autoimmunity. The model that we chose was the Non Obese Diabetic (NOD) 
mouse which closely resembles human automimmune type I diabetes in its 
pathology, immunology and genetics.  
 26
  
Our goal was to induce antigen specific T cell tolerance by delivering 
diabetogenic antigens to DCs in NOD mice, and thereby delay or prevent the 
development of diabetes. We chose the 9-23 insulin β chain peptide as our 
antigen for delivery to DCs since it has been reported in many studies to be 
the immunologically dominant epitope in the pathology of the disease in 
both mice and humans and there is a high degree of conservation of this 
epitope across species (134). To deliver this antigenic insulin epitope to DCs 
in vivo, we generated hybrid antibodies with the insulin peptide fused to the 
carboxyl terminus of the heavy chain of either the cloned αDEC (referred to 
as αDEC/INS) or the III/10 Isotype control (referred to as III/10/INS) heavy 
chain. The DNA constructs encoding these hybrid antibodies were 
transiently transfected into 293T cells, and the protein was purified from the 
supernatant (Figure 2A). 
 
To test whether the hybrid αDEC antibody bearing the insulin peptide was 
able to bind to the DEC-205 receptor, we did an in vitro binding assay on 
CHO cells that stably expressed the DEC-205 receptor on their surface. The 
αDEC/INS antibody was able to bind the DEC-205 receptor even at 
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concentrations as low as 0.1μg/ml, while the III/I0/INS antibody showed no 
binding even at a concentration of 5μg/ml (Figure 2B). 
 
To determine whether αDEC/INS targeting altered the onset of diabetes, we 
treated groups of 10 NOD females each, beginning at age 4 weeks, with  
αDEC/INS, or III/10 INS or PBS every 10 days. We injected doses ranging 
from 15μg to 0.005μg of αDEC/INS and III/I0/INS in multiple independent 
experiments. Mice were tested for urine glucose levels every week for upto 
25- 30 weeks. While the first experiment seemed to suggest that lower doses 
of αDEC/INS could retard the onset of diabetes (Figure 3A), this was not 
borne out by subsequent experiments (Figure 3B and C). We did not observe 
an abrogation or significant retardation in onset of diabetes. Thus delivery of 
insulin peptide to DCs in NOD mice did not result in protection against 
development of  diabetes.   
 
In summary, delivery of the MOG antigen to steady state DCs led to the 
absence of CD4 T cell accumulation in the spinal cord and the prevention of 
disease in the EAE model. In the NOD model however, delivery of insulin 
antigen to the DCs failed to block the development of diabetes. There are 
many possible reasons for this striking difference in outcomes between the 
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two disease models. One important difference is that in the NOD model, 
antigen is being delivered to DCs that are in a chronically inflamed 
environment, in contrast to the EAE model where inflammation only sets in 
upon induction of disease. Also in EAE which is an induced model of 
disease, the T cells do not see their antigen, until immunization, while in 
NOD, the insulin antigen is constantly in circulation from well before 
treatment begins. These and other considerations on the difference between 
the two disease models and its implications for treatment are discussed in 
detail in Chapter 6.  
Figure 1. Vaccination with αDEC/MOG prevents EAE in C57BL/6 wild 
type mice. 
A) Schematic representation of the αDEC/MOG hybrid antibody. 
B) Groups of 10 C57BL/6 mice each, were injected with either PBS or 
15μg of αDEC/MOG or III/I0/MOG, as indicated. 8 days after 
antibody or PBS injection the mice were challenged with 100μg 
MOG peptide in CFA s.c. along with Pertussis Toxin i.p. The mice 
were monitored for disease symptoms daily and scored on days 14 
and 21 post-immunization. The following clinical scale was used: 0-
no clinical signs, 1- flaccid tail, 2-hind limb weakness and abnormal 
gait, 3- complete hind limb paralysis, 4- complete limb paralysis. The 
scores were the same on days 14 and 21. Results represent scores 
from day 21.  
C) Some of the animals from the experiment described above were 
sacrificed on day 21 after disease induction and their spinal cords 
were removed, processed and analysed by flow cytometry. 
Histograms show intensity of staining with αCD4 APC among cells 
in the lymphoid gate. 
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Figure 1 
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Figure 2. Characterization of the hybrid αDEC/INS and III/I0/INS 
antibodies. 
A) SDS PAGE analysis of purified αDEC/INS and III/I0/INS hybrid 
antibodies followed by Coomassie staining. 
B) αDEC/INS and III/I0/INS antibodies were tested for in vitro binding to 
DEC-205 , expressed on CHO cells (Titration range 5μg/ml - 0.01 
μg/ml). Histogram plots show mean fluorescence intensity of staining 
with secondary •mouse IgG. 
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Figure 2 
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Figure 3. Chronic treatment with αDEC/INS did not prevent or delay 
onset of diabetes. 
(A, B and C)  Groups of 10 NOD females each, were injected every other 
week, beginning at 4 weeks of age, with the indicated doses of  αDEC/INS, 
III/I0/INS or PBS till they were 25 weeks old. Beginning at age 11 weeks, 
the mice were tested weekly for urine glucose levels, and a positive was 
scored if the mouse tested glucose high, two consecutive times in a row. 
Graphs represent 3 independent experiments with different doses of 
antibodies. 
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Figure 3 
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Chapter 4  
Results Part II 
 
Targeting of Antigen to DCs in NOD mice 
 
Prior to the studies described in this thesis, the consequences of antigen 
targeting to DCs had only been examined using transgenic T cell models. 
Our findings detailed in the previous chapter revealed the complexities of 
achieving tolerance in spontaneous wild type disease models with chronic 
inflammation such as NOD. We therefore decided to dissect the 
consequences of DC- targeted antigen delivery to polyclonal T cell 
repertoires at a cellular level in the NOD model. Since in NOD mice, the 
study of tolerance to insulin is complicated by a variety of factors, both 
genetic and immunological, we decided to first simply ask whether 
polyclonal T cells in NOD mice could be tolerized against a harmless 
foreign antigen by DC targeting.  
 
Towards this end, we set out to identify a foreign antigen that could generate 
detectable antigen specific T cell responses in a polyclonal NOD repertoire. 
The NOD MHC Class II molecule I-Ag7, has an unstable peptide binding 
groove due to a non-aspartic acid substitution at position 57 of the β chain 
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(135), which precludes high affinity binding with many antigenic epitopes. 
To find an antigen whose epitope could be presented by the I-Ag7, we 
screened a panel of hybrid αDEC antibodies bearing different antigenic 
proteins and peptides (HIV GAG p41, circumsporozoite protein from 
Plasmodium yoelii, ovalbumin protein from chicken egg, and myelin 
oligodendrocyte peptide) in B6.H2g7  mice. The B6.H2g7 congenic strain has 
the NOD H2g7 locus (H2g7 = Kd, I-Ag7, I-Enull and Db)  introgressed onto the 
C57BL/6 background (136). As controls we used C57BL/6 mice, known to 
generate either strong CD4 or CD8 T cell responses against all the antigens 
screened.  
 
We immunized the mice with 5μg of hybrid αDEC antibody in conjunction 
with 50μg of αCD40 antibody, as had been reported in C57BL/6 mice for 
the induction of  robust T cell responses (137, 138). The αCD40 antibody 
acts as an agonist for the CD40 receptor expressed on DCs. This interaction 
bypasses the need for the CD40 ligand on activated CD4 T cells to bind the 
receptor. αCD40 thus acts as a potent stimulator of DC maturation and 
thereby immunity. Two weeks after immunization bulk splenocytes isolated 
from the immunized mice were restimulated in vitro with αCD28 and 
antigenic peptides. Intracellular IFNγ responses were then assayed by flow 
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cytometry. The p41 protein of HIV GAG (GAG p41) was the only antigen 
amongst those tested that generated detectable IFNγ responses in CD4 T 
cells in B6.H2g7 (Figure 4A), while all other antigens (Figure 4B and data 
not shown) did not. We therefore chose to target GAG p41 to DCs to probe 
polyclonal T cell immunity and tolerance in NOD.    
 
NOD, B6.H2g7 and C57BL/6 mice were immunized with αDEC/GAG p41 
along with αCD40. Two weeks after immunization IFNγ and IL-2 levels in 
CD4 T cells were measured (Figure 5A, B and C). C57BL/6 mice made 
strong IFNγ responses, while the responses in B6.H2g7 were significantly 
lower (p value = 0.007). Interestingly, the IFNγ responses in NOD mice 
were even lower than those of the B6.H2g7 (p value=0.025) (Figure 5D). The 
diminished IFNγ responses of B6.H2g7 mice compared to the C57BL/6 mice 
confirm studies by others, showing that the I-Ag7 is a defective MHC 
molecule that leads to poor antigen presentation and dampened T cell 
responses (139).  The additional reduction in IFNγ responses in NOD CD4 T 
cells points to non-I-Ag7 defects in the mounting of immunity against foreign 
antigen in this strain. The defects are likely to lie in either the DCs or CD4 T 
cells or both, since the targeted antigen delivery strategy uniquely involves 
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these subsets. These results correlate with previous studies that have shown 
defects in vitro in APCs and CD4 T cells from NOD (140, 141). 
 
The NOD mouse has a recombinant MHC Class I locus consisting of H-2Kd 
and H-2Db. To determine whether the CD8 T cell compartment in NOD is 
also defective, we decided to immunize the mice with a recombinant 
adenovirus carrying the GAG p41 protein (Adeno/GAG p41), which had 
previously been reported to generate strong H-2Kd restricted IFNγ responses 
in BALB/c mice (138). NOD mice and BALB/c controls were immunized 
with a single intramuscular dose of the Adeno/GAG p41, and 2 weeks later 
bulk splenocytes were restimulated in vitro with GAG p41 peptides and 
assayed for intracellular IFNγ (Figure 6). The level of IFNγ made by the 
CD8 T cells in NOD was comparable to BALB/c, suggesting that unlike the 
CD4 T cell responses, the CD8 T cell responses against foreign antigen are 
not deficient in NOD.  
 
Having established detectable immune responses against the foreign GAG 
p41 antigen in the NOD CD4 polyclonal repertoire, we wanted to know 
whether targeting the antigen to DCs in the absence of adjuvant would lead 
to antigen-specific tolerance in NOD T cells, as had been observed in the 
 39
transgenic T cell models. A measure of such tolerance would be the 
abrogation of cytokine production in response to immunogenic challenge 
with antigen. We treated NOD mice with 5μg of αDEC/GAG p41, and 
waited 7 days for tolerance to be established, in accordance with empirical 
observations from the studies in transgenic models. The T cells were then 
subjected to immunogenic challenge in the form of αDEC/GAG p41 in 
conjunction with αCD40. 14 days after the challenge, bulk splenocytes were 
isolated and restimulated in vitro with GAG p41 antigenic peptides and IFNγ 
production was measured. NOD mice pretreated with the tolerizing regimen 
of αDEC/GAG p41 showed no reduction in IFNγ levels in response to 
challenge, when compared to control mice that had only received the 
challenge (Figure 7). 
 
The previous studies on T cell tolerance achieved by DC targeted antigen 
delivery had been done in models that involved adoptive transfer of 
transgenic T cells in wild-type mice (62, 106). The success in establishing 
tolerance in these model T cells, had led us to believe that antigen-specific T 
cells from autoreactive polyclonal repertoires could be tolerized in a similar 
fashion. The failure to achieve antigen-specific tolerance in the NOD mice, 
in the experiments detailed here, emphasized the challenges to achieving 
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tolerance in disease-prone repertoires that have multiple defects in their DCs 
and T cell compartments. These results also strongly brought into focus the 
many important differences between polyclonal T cell repertoires and the 
more simplistic transgenic models that had been studied before. Polyclonal T 
cells have a wide range of affinities and specificities compared to the high –
affinity, single epitope specificity of transgenic T cells. Another major 
difference in these experimental systems is that while adoptive transfer of 
transgenic T cells involves following the fate of an unreplenishing 
population of cells, wild type models have cells constantly emigrating from 
the thymus and being turned over. A detailed discussion of these differences 
and their potential impact on the establishment of tolerance is presented in 
chapter 6. The results described above, brought us to the conclusion that any 
attempt towards the challenge of tolerizing autoreactive disease-prone 
repertoires, would have to be based on a thorough understanding of 
tolerance in non-disease prone polyclonal repertoires. 
Figure 4. αDEC/GAG p41 generates IFNγ responses in B6.H2g7 mice.   
B6.H2g7 mice were immunized i.p. with 5μg of either  αDEC/GAG p41 (A) 
or  αDEC/OVA (B) in conjunction with 50μg  αCD40. 2 weeks later, bulk 
splenocytes were restimulated in vitro with either  αCD28 alone, or GAG 
p41 peptides with  αCD28, and cells were stained for intracellular IFNγ. 
Plots are gated on CD3 cells. 
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 43
Figure 5. αDEC/GAG p41 generates IFNγ responses in CD4 T cells in 
NOD mice. 
A) C57BL/6, B6.H2g7 and NOD mice (3 per group) were immunized i.p. 
with αDEC/GAG p41 (5μg) in  αCD40 (50μg). 2 weeks later bulk 
splenocytes were isolated and restimulated in vitro with GAG p41 
peptides. After 6 hours, cells were fixed and stained for intracellular 
IFNγ. Plots are gated on CD3 cells.  
B) Percentage of IFNγ producing T cells in C57BL/6, B6.H2g7 and NOD 
mice. Values represent means from 3 independent experiments as shown 
in (A) with 3 mice per group. Error bars represent one standard error of 
the mean. p-values were computed using Welch’s t-test (refer to Chapter 
2). 
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 45
Figure 6. Adeno/GAG p41 generates IFNγ responses in CD8 T cells in 
NOD. 
NOD and BALB/c mice were vaccinated using one i.m. dose (1X107 PFU) 
of Adeno/GAG p41. 14 days later, bulk splenocytes were isolated and 
restimulated with GAG p41 peptide for 6 hrs, and  intracellular IFNγ was 
measured by flow cytometry. Plots are gated on CD3 cells.  
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Figure 6 
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Figure 7. αDEC/GAG p41 does not tolerize αGAG p41-specific CD4 
IFNγ responses in NOD mice. 
NOD mice were injected i.p. with PBS or  αDEC/GAG p41 (5μg ). 7 days 
later, mice were immunized with αDEC/GAG p41 (5μg) and αCD40 
(50μg). 14 days later bulk splenocytes were restimulated with GAG p41 
peptide for 6 hrs, and intracellular IFNγ was measured by FACS. Plots are 
gated on CD3 cells. 
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Figure 7 
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Chapter 5 
Results Part III 
 
Tolerance in non-disease polyclonal repertoires 
 
Our results from the studies in the previous chapters emphasized the need to 
dissect the pathways and mechanisms of DC- mediated tolerance in 
polyclonal T cell repertoires in non-disease models, as the basis for progress 
towards achieving therapeutic tolerance in disease models. Towards this end, 
we chose to study tolerance in wild type C57BL/6 mice, with chicken egg 
ovalbumin (OVA) as the model antigen. Apart from being one of the most 
characterized antigens, OVA has the rare advantage of possessing both well- 
defined MHC Class I and II epitopes.  In choosing it for these studies, we 
therefore hoped to gain insight into the similarities and differences between 
the regulation of peripheral tolerance in the CD4 and CD8 T cell 
compartments.  
 
To deliver OVA protein to DCs in vivo, a hybrid antibody was produced as a 
fusion protein with the full length OVA protein added to the carboxyl 
terminus of the heavy chain of the cloned αDEC (referred to as 
αDEC/OVA) antibody (Figure 8A). The DNA construct encoding this 
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hybrid antibody was transiently transfected into 293T cells, and the protein 
was purified from the supernatant (Figure 8B).  
 
We tested binding of hybrid αDEC antibody bearing the OVA protein, to the 
DEC-205 receptor in an in vitro assay. We used CHO cells expressing the 
DEC-205 receptor on their surface. αDEC/OVA was able to bind the DEC-
205 receptor even at concentrations as low as 0.1μg/ml (Figure 8C). 
 
We immunized C57BL/6 mice with 5μg of αDEC/OVA in conjunction with 
αCD40, to see whether we could detect measurable cytokine responses in 
the polyclonal repertoire against the CD4 and CD8 T cell epitopes of OVA. 
2 weeks later we isolated bulk splenocytes and restimulated in vitro with a 
mix of αCD28 and peptide 75 (epitope 265-279) consisting of overlapping 
Class I and II epitopes of OVA. αCD28, the TCR-independent T cell 
costimulator  (142) , was used to enhance T cell responses to facilitate 
detection. In response to immunization with αDEC/OVA, the CD4 T cells 
make low but detectable levels of IFNγ, and medium to high levels of IL-2 
(Figure 9A and B). In the case of CD8 T cells, IFNγ responses are very 
strong and IL-2 responses are undetectable. (Fig. 9C and data not shown).   
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 We also tried immunizations with DC maturation stimuli milder than 
αCD40, specifically the TLR ligands polyIC and LPS, and Complete 
Freund’s Adjuvant (CFA). These adjuvants had been shown to generate 
robust transgenic T cell responses in conjunction with DC targeted antigen, 
(62, 106) and our hope was that they would also prove effective in 
generating polyclonal responses in our assays. However, no detectable 
cytokine production was seen in response to any of these adjuvants (data not 
shown) leading us to conclude that in order to visualize primary polyclonal 
responses, a potent adjuvant such as αCD40 was necessary. 
 
Having established detectable polyclonal CD4 and CD8 T cell cytokine 
responses against immunogenic OVA, we wanted to examine whether 
targeting the antigen to DCs in the absence of adjuvant would lead to 
antigen-specific tolerance. A measure of such tolerance would be the 
abrogation of cytokine production in response to subsequent immunogenic 
challenge with antigen. We treated C57BL/6 mice with 5μg or 20μg of 
αDEC/OVA and waited 10 days for tolerance to be established. The T cells 
were then subjected to immunogenic challenge in the form of 5μg 
αDEC/OVA in conjunction with αCD40. 14 days after the challenge, bulk 
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splenocytes were isolated and restimulated in vitro with αCD28 and the 
OVA peptide 75 bearing the Class I and II epitopes, and IFNγ and IL-2 
production was measured. Neither CD4 nor CD8 T cells from mice 
pretreated with the tolerizing regimen of αDEC/OVA, showed reduction in 
the levels of IFNγ in response to challenge, when compared to IFNγ levels 
from control mice that had only received the challenge (Figure 10A and data 
not shown). Interestingly however, the CD4 T cells from mice pretreated 
with the tolerizing regimen of αDEC/OVA, showed a reduction in IL-2 
levels when compared to control mice that had only received the challenge.  
(Figure 10B). The results were similar for mice treated with 5μg or 20μg of 
αDEC/OVA preceeding immunization. Thus polyclonal wild type CD4 T 
cells, when exposed to antigen in the absence of adjuvant are not deleted but 
persist, and can respond to subsequent immunogenic challenge by producing 
high levels of IFNγ, but can no longer make IL-2. This outcome is very 
different from what we see in adoptively transferred transgenic T cells after 
exposure to tolerizing antigen, where the T cells are either deleted, or persist 
having lost all ability to make cytokines. 
 
We decided to examine a panel of cytokines to see whether in addition to  
IL-2, T cells exposed to tolerizing antigen lost or gained the ability to make 
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other cytokines. We treated the mice with 5μg of αDEC/OVA in the absence 
of adjuvant and 10 days later, immunized them with αDEC/OVA in 
conjunction with αCD40. 14 days later, we isolated bulk splenocytes and 
cultured them with peptide for 72 hours, after which the supernatants were 
tested on a high-throughput LUMINEX assay for IFNγ, IL-10, IL-17, IL-4, 
IL-12 and TNFα. Mice that had received the tolerizing regimen prior to 
challenge, made low but detectable levels of IL-10 while mice that had 
received only the challenge did not. All the other cytokines examined such 
as TNFα were produced at comparable levels in both groups of mice (Figure 
11 and data not shown). Thus in polyclonal T cells, the exposure to antigen 
under tolerizing conditions alters the cells’ effector cytokine profile. The 
cells continue to make IFNγ, but lose the ability to make IL-2, while gaining 
the ability to make IL-10.  
 
IL-10 is a anti-inflammatory cytokine induced under tolerogenic conditions 
in certain subsets of suppressor T cells (129). Thus the presence of this 
cytokine in mice exposed to the tolerizing regimen, suggested a skewing of 
the Th1 polarized IFNγ response towards a pro-tolerance cytokine milieu. 
We looked to see whether there was an increase in the numbers of 
CD4+CD25+Foxp3+ cells, however we failed to see any difference in 
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immunized mice compared to mice that had been exposed to αDEC/OVA 
before immunization (data not shown).  
 
To determine whether the alteration in effector cytokines upon tolerizing 
antigen exposure, resulted in functional tolerance for the CD4 T cells, we 
decided to examine antibody responses in these mice. B cells need CD4 T 
cell help in order to make antibodies, and therefore if the CD4 T cells in our 
mice are functionally tolerized, we would hypothesize that antibody 
production in these mice would be diminished. C57BL/6 mice that are 
immunized with either αDEC/OVA in conjunction with αCD40, or OVA 
protein in alum followed by a boost 14 days later with NP-OVA, generate 
OVA-specific and NP-specific antibodies, the peak titres of which are 
between 14 and 21 days after the boost. Since αCD40 is a very potent 
adjuvant, we worried that tolerized T cells exposed to it upon immunization, 
might reverse tolerance. Alum on the other hand is an appropriately mild 
adjuvant, and has been shown to produce detectable antibody titres, albeit 
one order of magnitude lower than those produced by αCD40 (137). We 
therefore chose to use both immunization protocols in mice pretreated with 
tolerizing OVA, and expected to see a more dramatic reduction of antibody 
titres in response to alum immunization as compared to αCD40 
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immunization. We treated groups of 8 mice each, with either PBS, a single 
dose of αDEC/OVA or three sequential doses of αDEC/OVA. The duration 
between each dose of αDEC/OVA was 10 days. 10 days after the final dose, 
we immunized the mice with either αDEC/OVA in conjunction with αCD40 
or OVA in alum. 14 days later, the mice were boosted with NP-OVA, and 
bled at day 14 post-boost. Anti-OVA and anti-NP antibody titres were then 
measured using a capture ELISA with either OVA, or NP conjugated to 
BSA respectively. We found that mice exposed to tolerizing antigen (single 
or multiple doses) prior to immunization, showed between one and two log 
diminished antibody titres, with both immunization regimens. The reduction 
in antibody titres was greater in the case of the alum immunization, as 
compared to the αCD40 immunization (Figure 12) Our results indicate that 
treatment with αDEC/OVA in the absence of adjuvant leads to a special 
form of anergy in polyclonal repertoires, where the CD4 T cells experience 
not just an alteration in cytokine profiles, but also a loss in functional ability 
to aid the B cells in mounting humoral responses.  
 
We then decided to examine in vitro proliferative responses to antigenic 
restimulation in CD4 and CD8 T cells from mice that had been exposed to 
tolerizing antigen. We treated the mice with αDEC/OVA and 10 days later, 
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immunized with αDEC/OVA in conjunction with αCD40. 14 days later, 
bulk splenocytes were labeled with CFSE and pulsed with peptide with or 
without αCD28 in vitro. 3 days later, cells were assayed for proliferation by 
flow cytometry. We observed that both CD4 and CD8 cells that had been 
exposed to tolerizing antigen prior to immunization, when pulsed with 
αCD28, made stronger proliferative responses when compared to cells from 
mice that had received only immunization. In contrast in the absence of 
αCD28, tolerized mice showed a complete abrogation of proliferation in 
both the CD4 and CD8 compartment (Figure 13 and 14). We therefore 
conclude that tolerizing exposure to antigen in the polyclonal repertoire 
leads to functional tolerance in both CD4 and CD8 T cells, one measure of 
which is in vitro proliferation. αCD28, a potent stimulator of TCR-
independent signaling in T cells, reverses proliferative arrest in the tolerized 
mice. There are two explanations for this observation. Either, the αCD28 is 
reversing anergy in the tolerized T cells, by pushing them into cycle, or it is 
activating a hypo-responsive population of antigen-specific T cells, that had 
hitherto been unresponsive to the antigen. The observation that cells from 
tolerized mice that have seen antigen twice, i.e. during tolerization as well as 
immunization, make stronger proliferative responses in the presence of 
αCD28 than cells from immunized mice that have seen antigen only once, 
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seems to suggest that the former explanation is more likely. Thus tolerized 
CD4 and CD8 T cells, appear to be in a state of anergy that can be reversed 
upon exposure to αCD28 mediated costimulation. 
 
The results in this chapter show that polyclonal CD4 and CD8 T cells can be 
tolerized by antigen delivered to DCs in the absence of inflammation. The 
mechanisms and phenotype of this tolerance is very different from that seen 
in the previously examined transgenic T cell models. Unlike transgenic T 
cells which are either deleted or completely anergized, with no effector 
responses in vivo and in vitro, polyclonal T cells persist after tolerance but 
alter their cytokine profile. They continue to make IFNγ in response to 
immunogenic challenge, but lose the ability to make IL-2, while gaining the 
ability to make IL-10. The functional outcome of this tolerance is the loss of 
CD4 T cell help to the antibody producing B cells. Thus antibody titres in 
tolerized mice are significantly reduced. αCD40 as an adjuvant seems to 
reverse tolerance to some extent, since in mice immunized with alum, there 
is a more dramatic reduction in antibody titres compared to mice immunized 
with αCD40. Tolerized CD4 and CD8 cells lose their ability to proliferate in 
vitro in response to peptide restimulation. However restimulation in the 
presence of αCD28 appears to reverse the proliferative block on the anergic 
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T cells in vitro. These results suggest that this form of polyclonal tolerance 
is very delicately held in balance and strong stimulation of the T cells  under 
conditions such αCD40 in vivo or αCD28 in vitro  can reverse this tolerance 
in both CD4 and CD8 subsets. 
 
This susceptibility to reversal of T cell tolerance in wild type mice as 
compared to transgenic models, could be explained by the nature of 
polyclonal T cells. These cells range in affinities and specificities, with the 
average affinity being lower than that of most high affinity, single specificity 
transgenic T cells. In the case of transgenic T cells, strong signaling during 
high affinity interactions with tolerizing antigen leads to deletion or 
complete anergy. In contrast, in lower affinity polyclonal T cells, weaker 
strength of signaling during interactions with tolerizing antigen may lead to 
partial anergy that can be reversed under conditions of strong costimulation.  
Thus polyclonal T cell tolerance has different mechanisms and differing 
dynamics of establishment and reversal compared to transgenic models, and 
the understanding of these differences is an important step towards 
achieving tolerance in disease prone polyclonal repertoires and the therapy 
of autoimmune disease. 
Figure 8. Design and characterization of the αDEC/OVA hybrid 
antibody.  
A) Schematic representation of the αDEC/OVA hybrid antibody. 
B) SDS PAGE analysis of purified αDEC/OVA hybrid antibody followed 
by Coomassie staining. αDEC was used as a loading control.  
C) αDEC/OVA antibody was tested for in vitro binding to DEC-205 
expressed on CHO cells (Titration range 5μg/ml - 0.01 μg/ml). Histogram 
plots show mean fluorescence intensity of staining with secondary 
αmouse IgG. 
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Figure 8 
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Figure 9. αDEC/OVA generates detectable IFNγ and IL-2 responses in 
CD4 and CD8 cells in C57BL/6 mice. 
C57BL/6 mice were immunized i.p with αDEC/OVA (5μg) along with 
αCD40 (50μg). Two weeks later bulk splenocytes were isolated and 
restimulated in vitro with OVA peptide 75 containing Class I and II 
epitopes. After 6 hours cells, were fixed and stained for intracellular IFNγ 
and IL-2. Plots are gated on CD3 cells.  
(A) IFNγ in CD4 cells. (B) IL-2 in CD4 cells. (C) IFNγ in CD8 cells. 
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Figure 10. CD4 T cells from C57BL/6 mice treated with αDEC/OVA 
prior to immunization, show reduced levels of IL-2 but not IFNγ, 
following tolerization regimen.  
C57BL/6 mice were injected with αDEC/OVA (5μg). 10 days later, mice 
were immunized with αDEC/OVA (5μg) in conjunction with αCD40 
(50μg). 14 days later, bulk splenocytes were isolated and restimulated in 
vitro for 6 hrs, with αCD28 and the OVA peptide 75 bearing the Class I and 
II epitopes. Intracellular IFNγ (A) and IL-2 (B) was measured by flow 
cytometry. Plots are gated on CD3 cells. 
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Figure 11. CD4 T cells from C57BL/6 mice treated with αDEC/OVA 
prior to immunization, show increased levels of IL-10, following 
tolerization regimen. 
C57BL/6 mice were injected with  PBS or αDEC/OVA (5μg). 10 days later, 
mice were immunized with αDEC/OVA (5μg) in conjunction with αCD40 
(50μg). 14 days later, bulk splenocytes were isolated and restimulated in 
vitro for 72 hrs, with medium or the OVA peptide 75 bearing the Class I and 
II epitopes. Supernatants were then assayed by LUMINEX for IL-10 and 
TNFα. Values represent mean cytokine concentrations with 4 mice per 
group. Error bars represent one standard error of the mean. 
 66
Figure 11 
 
 
 
 67
Figure 12. Single or multiple doses of αDEC/OVA prior to 
immunization, abrogates antibody production in C57BL/6 mice.  
Schematic representation of the protocols for tolerance induction, followed 
by immunization with αDEC/OVA along with αCD40 (A), or OVA in alum 
(D).  
Groups of 8 mice each were treated with either PBS, a single dose of 
αDEC/OVA or three sequential doses of αDEC/OVA at 10 day intervals. 10 
days after the final dose, mice were immunized with either αDEC/OVA 
along with αCD40, or OVA in alum. 14 days later, the mice were boosted 
with NP11-OVA. Mice were bled 14 days post-boost. Symbols represent the 
log of αOVA  titres (B and E) and αNP titers (C and F) of individual mice  
as measured by ELISA. Horizontal bars depict the mean of the log of the 
antibody titers for each group. 
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Figure 13. CD4 T cells from mice treated with αDEC/OVA prior to 
immunization, do not proliferate in vitro in response to antigen. 
Mice were treated with PBS or αDEC/OVA (5μg) and 10 days later, 
immunized with αDEC/OVA (5μg) along with αCD40 (50μg). 14 days after 
immunization, bulk splenocytes were labeled with CFSE and pulsed with 
peptide with or without αCD28 in vitro. 3 days later, cells were assayed for 
proliferation by flow cytometry. Plots are gated on CD3+CD4+ cells. 
Identical gates have been applied to all samples. 
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Figure 14. CD8 T cells from mice treated with αDEC/OVA prior to 
immunization, do not proliferate in vitro in response to antigen. 
Mice were treated with PBS or αDEC/OVA (5μg) and 10 days later, 
immunized with αDEC/OVA (5μg) along with αCD40 (50μg). 14 days after 
immunization, bulk splenocytes were labeled with CFSE and pulsed with 
peptide with or without αCD28 in vitro. 3 days later, cells were assayed for 
proliferation by flow cytometry. Plots are gated on CD3+CD8+ cells. 
Identical gates have been applied to all samples. 
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Figure 14 
 
 
 
  
 73
Chapter 6 
Discussion 
 
The intricate regulation of the immune system’s ability to distinguish self 
from non-self is at the heart of what protects the animal from infection while 
preserving it from self-destruction. The establishment and maintenance of 
tolerance to self is a process that begins during fetal development and 
continues through the life of the animal. The negative selection of 
autoreactive T cells in the thymus, is a principal mechanism for the 
establishment of tolerance, nevertheless not every autoreactive T cell is 
deleted in the thymus. Some make it to the periphery, and in genetically pre-
disposed individuals or special circumstances of inflammation and infection, 
can lead to autoimmunity. The establishment and maintenance of peripheral 
tolerance is therefore critical for the prevention of autoimmune disease.  
 
An important fork in the divergent paths to immunity and tolerance in the 
periphery is the presentation of antigen to the T cells by the DCs. The 
context of the DCs during this presentation has been shown to be critical in 
the decision between tolerance and immunity. We have devised a strategy to 
deliver antigens specifically to DCs in situ, based on a genetically 
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engineered hybrid antibody comprising the variable region specific for the 
DEC-205 receptor on DCs, a constant region that was mutated to prevent 
binding to Fc receptors, and antigenic protein or peptide fused to the 
carboxyl terminus of the heavy chain. Using models of adoptive transfer of 
transgenic T cells into wild type mice, it was shown that antigen presentation 
by DCs in the steady state leads to tolerance, while presentation during 
inflammation leads to immunity. The fate of tolerized transgenic T cells was 
either deletion, or complete anergy. The anergy observed in these models 
was complete paralysis of the T cells, where they ceased to proliferate or 
make cytokines in response to subsequent challenge with immunizing 
antigen both in vivo and in vitro.  
 
These results in transgenic models suggested a promising novel approach to 
prevention and therapy of autoimmune diseases. Our rationale was that 
delivering autoantigens to DCs using the targeting strategy would lead to 
tolerance of autoreactive T cells in the periphery, and the consequent 
prevention of progression to autoimmune disease. To evaluate this strategy 
of DC- targeted antigen therapy, we chose the experimental autoimmune 
encephalomyelitis (EAE) mouse model for human multiple sclerosis (MS). 
MS is an autoimmune condition affecting the central nervous system, with a 
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relapsing-remitting or progressive course that often leads to paralysis or 
even death. It is characterized by de-myelination of the neuronal sheath and 
the presence of multiple scarred areas in the brain infiltrated by T cells and 
macrophages. The EAE model of multiple sclerosis, is an acute model 
induced by immunization with brain specific proteins and peptides (143, 
144), including a peptide from myelin oligodendrocyte glycoprotein (pMOG 
35-55) (145). 
 
To deliver MOG peptide to DCs in vivo, hybrid antibodies were produced 
with the MOG peptide fused to the carboxyl terminus of the cloned αDEC 
antibody (αDEC/MOG) (Figure 1A). Our results demonstrate that treatment 
of C57BL/6 mice with αDEC/MOG prior to immunization with MOG 
peptide, protects them from developing disease (Figure 1B). Also treatment 
with αDEC/MOG prevents accumulation of effector CD4 T cells in the 
spinal cord (Figure 1C).  
 
Our success in the prevention of EAE, led us to then investigate the 
therapeutic potential of the DC based antigen delivery strategy in the Non-
Obese Diabetic (NOD) mouse model. The NOD mouse is an important 
model of autoimmune Type 1 diabetes because it shares many genetic, 
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immunological and pathological similarities with the human disease (146-
150). The destruction of the insulin producing β cells in the pancreatic islets 
by autoreactive CD4 and CD8 T cells leads to the disease. Diabetes onset 
typically occurs at 12 to 14 weeks of age in female mice and slightly later in 
male mice. Beginning as early as 3-4 weeks of age, both female and male 
NOD mice demonstrate mononuclear infiltrates that surround the islet (peri-
insulitis). These infiltrates progress and invade the islets (insulitis) over the 
subsequent few weeks. 60%-80% of females and 20- 30% males ultimately 
progress to overt diabetes (146).  
 
One of the most important loci in the genetic susceptibility to diabetes in 
NOD, is H-2g7, the MHC locus. The MHC Class II I-Ag7 molecule encoded 
by this locus has a low-affinity peptide binding groove, which has been 
suggested to be involved in defective negative selection of autoreactive T 
cells in the thymus (151, 152). Some of the major autoantigens implicated in 
the pathogenesis of T1D are insulin, glutamic acid decarboxylase, 
insulinoma-associated protein 2, IGRP and heat shock protein 60 (134).  
 
To evaluate the therapeutic potential of the dendritic cell- targeted antigen 
delivery strategy in the chronic spontaneous diabetes model, the 9-23 
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peptide of the β chain of insulin was selected as the antigen of choice. This 
peptide has both CD4 and CD8 immunodominant epitopes that have been 
implicated in the disease (134). A hybrid antibody was produced with the 
insulin peptide fused to the carboxyl terminus of the cloned αDEC antibody 
(αDEC/INS) (Figure 2A). Chronic treatment of NOD mice with αDEC/INS 
starting at age 5 weeks, failed to delay or prevent onset of diabetes (Figure 
3A, B and C).  
 
The failure of the autoantigen targeting strategy in NOD in contrast to EAE, 
pointed to the complexities of the NOD disease model and the challenge of 
tolerizing disease-prone polyclonal repertoires. The EAE model is an acute 
induced model of autoimmunity, which means that the system is in a non-
inflamed steady state conducive to the induction of tolerance, until the time 
when immunity- induced inflammation sets in. Also until induction of 
disease, the MOG specific T cells are ignorant of their antigen, since it is 
sequestered behind the blood-brain barrier. Thus when the MOG antigen is 
presented for the first time, by  steady state DCs to MOG-specific T cells in 
the periphery, the outcome is tolerance.  
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In striking contrast, the NOD model, which mimics progressive human 
autoimmune disease, has a chronically inflamed immunological environment 
from the time the mice are as young as 3-4 weeks old. Thus the DCs in this 
model are most likely in a chronic state of activation, while the insulin- 
specific T cells encounter their circulating antigen via the DCs even before 
treatment with αDEC/INS begins. Also in the EAE model the pathogenic T 
cells that are induced by MOG peptide immunization, are of a single 
specificity, and are addressed by the MOG peptide delivered through DC 
targeting. In the NOD model of spontaneous autoimmunity however, 
pathogenesis is caused by autoreactive T cells of varying islet specificities. 
We had hoped that since the 9-23 epitope in insulin is immunodominant, 
tolerizing autoreactive T cells against this epitope would suppress T cells 
with other specificities as well (153). However, therapy in NOD using DC 
based delivery of antigens, might require a combination of islet antigens in 
order to be successful.  
 
Our results made us realize that achievement of peripheral tolerance in NOD 
is complicated by several factors, and insights into successful DC-based 
therapeutic strategies would have to come from a thorough understanding of 
DC regulation of peripheral T cell responses in NOD. 
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 To examine polyclonal T cell tolerance in NOD without the complicating 
variables associated with autoantigens, we asked whether foreign antigen-
specific peripheral tolerance could be achieved. The antigen that was chosen 
for targeting to the DCs was the HIV GAG p41 protein which generated 
detectable IFNγ responses in the I-Ag7-restricted CD4 compartment in 
B6.H2g7 mice (Figure 4A). Consistent with in vitro studies by others (139), 
the presence of the I-Ag7 molecule in the C57BL/6 background (B6.H2g7) 
severely dampens T cell responses in comparison to those in wild type 
C57BL/6 mice. However, the NOD mice appear to have additional 
suppression of T cell responses compared to the B6.H2g7 mice (Figure 5). 
These results indicate that not only is the MHC II in NOD mice defective, 
but there are likely other defects in the DC and CD4 T cell compartments. 
Others have reported defects in in vitro antigen presentation and 
costimulation by NOD APCs. There have also been reports of enhanced 
cytokine effector responses upon non-specific TCR stimulation in NOD as 
compared to B6.H2g7 (141, 152). Our results in vivo however show 
dampened IFNγ responses to immunizing antigen targeted to NOD DCs. In 
the future it would be interesting to dissect whether the in vivo defect in 
responsiveness that we see, lies in the DC or the CD4 compartment. 
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 To examine tolerance against the foreign GAG p41 antigen, NOD mice were 
pretreated with αDEC/GAG p41 without adjuvant, prior to immunization 
with αDEC/GAG p41 in conjunction with αCD40. This treatment with 
αDEC/GAG p41 does not alter the ability of CD4 T cells to make IFNγ in 
response to immunogenic challenge (Figure 7). Thus the effector cytokine 
response in NOD was not altered by DC targeted antigen delivery, under the 
conditions examined.  
 
The failure to achieve tolerance in the disease- prone NOD repertoire, 
brought into strong focus the need to study polyclonal tolerance in a non-
disease prone model. Thus far all the studies on antigen targeting to DCs 
have involved transgenic T cell models. In those simplistic systems tolerance 
resulted in either deletion or complete anergy of the T cells, characterized by 
a loss of proliferation and cytokine production. However, polyclonal models 
have several complicating factors. Firstly, polyclonal T cells respond to 
several different epitopes in an antigen, while transgenic T cells respond to a 
single one. Thus tolerizing transgenic T cells is less challenging. Secondly, 
for the same epitope specificity, there is a wide range of affinities amongst 
poylconal cells, while transgenic T cells are of single specificity and high 
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affinity. There is evidence that high affinity T cells upon interaction with 
tolerizing antigen get deleted and thus tolerized, while lower affinity T cells 
are not deleted but persist, and under certain conditions of inflammation 
respond to immunogenic stimuli (154). Thirdly, experiments involving 
transgenic T cells have always been carried out by adoptively transferring 
these cells into a wild type mouse and then tracking their fate. This is 
therefore a closed system which receives no input from the thymus, unlike 
polyclonal wild type repertoires that are constantly being replenished from 
the thymus (155).  In a system of induced peripheral tolerance such as the 
one studied here, the influx of naïve antigen specific T cells from the 
thymus, although infrequent, could potentially lead to a reversal of tolerance 
upon challenge. For all these reasons, establishment and maintenance of 
tolerance in polyclonal models is considerably more difficult to achieve 
when compared to tolerance in transgenic T cells. 
 
We therefore decided examine in detail, the establishment and maintenance 
of wild type polyclonal tolerance, to glean insights into the pathways of 
immune regulation. C57BL/6 mice were studied for responses against the 
CD4 and CD8 epitopes of OVA. Treatment with αDEC/OVA prior to 
immunization with αDEC/OVA in conjunction with αCD40, leads to an 
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alteration in the cytokine profile of the CD4 and CD8 T cells. Both CD4 and 
CD8 T cells continue to make IFNγ while IL-2 levels are diminished in the 
CD4 compartment (Figure 10). IL-2 is required to maintain proliferative 
responses during clonal expansion in response to antigen challenge and for T 
cell survival in vivo. In the absence of IL-2, effector CD4 and CD8 T cells 
cannot survive long enough to become memory (156-158). Thus despite the 
fact that the tolerized T cells continue to make IFNγ  in the short-term (14 
days), the lowered ability to make IL-2 probably impacts the longevity of 
these cells, ultimately leading to death.  
 
Since its discovery IL-2 was thought to be solely a pro-immune cytokine, 
until that role was challenged by studies showing that mice deficient in IL-2 
or its receptor components develop lymphoproliferative diseases and 
autoimmunity (159, 160). Recent reports have explained this immuno-
suppressive role of IL-2, by demonstrating that it is crucial to the 
development, survival and function of CD4+CD25+ T regulatory cells 
(Tregs) (161). These results are now widely interpreted to be indicative that 
IL-2 is crucial only for tolerance and not for immunity in vivo (161). Our 
results however suggest that IL-2 might be required to maintain T cell 
responses in vivo as functional tolerance correlates with the absence of this 
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cytokine. There maybe a intricate balance between the effects of IL-2 on 
Tregs versus effector T cells in vivo. Depending on whether IL-2 levels are 
limiting, tolerance or immunity dominate. To test if the abrogation of T cell 
responsiveness that we see in our system, is due to the loss of IL-2, we plan 
to examine the consequences of  supplying exogenous IL-2 in vivo.  We 
hypothesize that if the loss of IL-2 is responsible for the tolerance 
established in vivo, then exogenous IL-2 would result in rescue of T cell 
responsiveness.  
 
To examine whether other cytokines produced by the T cells were altered 
after tolerizing regimen of antigen, we tested a panel of different cytokines. 
Tolerized T cells gained the ability to make low levels of IL-10, when 
compared to immunized T cells. None of the other cytokines tested were 
altered after exposure to the tolerizing regimen (Figure 11). IL-10 is a pro-
tolerance cytokine made by a subset of regulatory T cells under tolerogenic 
conditions, that has been shown to suppress inflammatory responses in vivo 
(129). We did not find an increase CD4+CD25+Foxp3+ regulatory cells in 
mice that had been tolerized, indicating that the tolerance we see is possibly 
mediated by an alteration in the cytokine mileu and the balance between 
effector and suppressor cytokines such as IL-2 and IL-10. 
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 CD4 T cells that have been exposed to tolerizing antigen prior to 
immunogenic challenge, lose their ability to provide help to B cells for 
antigen-specific humoral responses. Mice receiving αDEC/OVA prior to 
immunization had significantly diminished antibody titres compared to mice 
that had only been immunized (Figure 12). Therefore targeting of antigen to 
DCs in the steady state leads to polyclonal CD4 T cell tolerance, as well as 
tolerance of the humoral responses against antigen. 
 
The antibody titres were more diminished in the case of tolerized mice that 
had been immunized with OVA in alum, compared to mice that had received 
αDEC/OVA along with αCD40 (Figure 12). Thus the exposure of tolerized 
polyclonal CD4 T cells to αCD40, which is a potent activator of DCs,  
appears to induce some degree of reversal of tolerance in vivo. This result is 
supported by a study on polyclonal CD8 T cells showing that high affinity T 
cells are deleted in response to tolerizing antigen, while low affinity cells are 
not deleted but persist, and can be reactivated upon potent costimulation 
(154).  
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CD4 and CD8 cells pretreated with the tolerizing regimen, failed to make 
proliferative responses in vitro in response to peptide restimulation, 
demonstrating that as a consequence of tolerance, T cells lose their ability to 
cycle. This can be explained by the loss of IL-2, since it has been shown to 
be indispensable for in vitro proliferation and differentiation of T cells (162). 
Surprisingly, when  CD4 and CD8 T cells were pulsed in vitro with peptide 
in the presence of αCD28, the cells made stronger proliferative responses in 
the tolerized mice compared to the immunized mice (Figure 13 and 14). 
Thus both CD4 and CD8 T cells that are tolerized,  fail to proliferate in vitro 
upon restimulation with antigen. However, αCD28 can reverse the 
abrogation in proliferation. There are two explanations for this observation. 
Either, the αCD28 is reversing anergy in the tolerized T cells, by pushing 
them into cycle, or it is activating a hypo-responsive population of antigen-
specific T cells, that had hitherto been unresponsive to the antigen. The 
observation that cells from tolerized mice that have seen antigen twice, i.e. 
during tolerization as well as immunization, make stronger proliferative 
responses in the presence of αCD28 than cells from immunized mice that 
have seen antigen only once, seems to suggest that the former explanation is 
more likely. Thus tolerized CD4 and CD8 T cells, appear to be in a state of 
anergy that can be reversed upon exposure to αCD28 mediated 
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costimulation. αCD28 is a potent costimulator of T cell activation that is 
involved in stabilization of cytokine mRNA and long-lasting IL-2 secretion 
and proliferation. Thus in the case of the tolerized CD4 and CD8 T cells, 
αCD28 might be removing the proliferative block on the cells, by restoring 
IL-2 secretion (142). 
 
Concluding Remarks 
Our results demonstrate that polyclonal T cell tolerance in a wild type 
repertoire can be achieved by targeting of antigen to DCs in the steady state. 
This tolerance seems to be a form of non-deletional, partial anergy. Unlike 
anergic transgenic T cells, these cells do not completely lose their ability to 
make cytokines. Instead they continue to make IFNγ while losing the ability 
to make IL-2, and gaining the ability to make IL-10. This partial anergy can 
be reversed with strong costimulatory stimuli, such as αCD40 in vivo and 
αCD28 in vitro.  
 
This susceptibility to reversal of T cell tolerance in wild type mice as 
compared to transgenic models, could be explained by the nature of 
polyclonal T cells. Polyclonal cells range in affinities and specificities, with 
the average affinity being lower than that of most high affinity, single 
 87
specificity transgenic T cells. In the case of transgenic T cells, strong 
signaling during high affinity interactions with tolerizing antigen leads to 
deletion or complete anergy. In contrast, in lower affinity polyclonal T cells, 
weaker strength of signaling during interactions with tolerizing antigen may 
lead to partial anergy that can be reversed under conditions of strong 
costimulation.  
 
Our results with polyclonal T cell tolerance in a non-disease prone 
repertoire, provide an important understanding of the mechanisms and 
regulation of peripheral tolerance in wild type mice. They offer critical 
insight into why the establishment and maintenance of tolerance in models 
with chronic inflammation and low affinity T cell repertoires such as NOD, 
is a challenge.  This understanding is an important step towards the 
successful design of antigen-specific DC based therapeutic strategies for 
prevention and treatment of autoimmune disease.  
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